GSK plc Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Oct 7, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Oct 7, 2025 |
| Risk Level | low |
| Pages | 10 |
| Reading Time | 12 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, transaction-in-own-shares
TL;DR
GSK is buying back its own stock via BNP Paribas.
AI Summary
On October 7, 2025, GSK plc announced its purchase of its own ordinary shares through its broker, BNP Paribas SA. The filing does not specify the number of shares purchased or the total dollar amount involved in this transaction.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This is a routine disclosure of share repurchases, a common corporate action.
Key Players & Entities
- GSK plc (company) — Company making the share purchase
- BNP Paribas SA (company) — Broker executing the share purchase on behalf of GSK
- October 2025 (date) — Reporting period for the transaction
FAQ
What was the total number of GSK plc ordinary shares purchased?
The filing states that GSK plc purchased ordinary shares but does not specify the total number of shares bought.
What was the total dollar amount spent on the share repurchase?
The filing does not disclose the total dollar amount of the share repurchase.
What is the principal executive office address of GSK plc?
The principal executive office of GSK plc is located at 79 New Oxford Street, London, WC1A 1DG.
Does GSK plc file annual reports under Form 20-F?
Yes, GSK plc indicates it files annual reports under Form 20-F.
Who acted as the broker for GSK plc's share repurchase?
BNP Paribas SA acted as the broker for GSK plc's transaction in its own shares.
Filing Stats: 3,068 words · 12 min read · ~10 pages · Grade level 2.8 · Accepted 2025-10-07 06:14:57
Filing Documents
- a2743c.htm (6-K) — 4498KB
- 0001654954-25-011522.txt ( ) — 4499KB
From the Filing
IN OWN SHARES a2743c     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934       For the month of October 2025   Commission File Number 001-15170     GSK plc (Translation of registrant's name into English)     79 New Oxford Street, London, WC1A 1DG (Address of principal executive office)       Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F . . . .X. . . . Form 40-F . . . . . . . .       Transaction in own shares   GSK plc (the " Company ") announces today   acting through BNP Paribas SA (the " Broker "), it has purchased the following number of the Company's ordinary shares of  31¼  pence each.   Date of purchase: 06 October 2025 Aggregate number of ordinary shares of  31¼  pence each purchased: 340,000 Lowest price paid per share (GBp): 1,594.00p Highest price paid per share (GBp): 1,624.50p Volume-weighted average price paid per share (GBp): 1,614.05p   The purchased shares will be held   as Treasury shares.                                                                                                                            Such purchase forms part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker, as announced on 30 September 2025. Since 30 September 2025, the Company has purchased 1,592,000 ordinary shares.   Following the above purchase, the Company will hold 249,056,844 ordinary shares in treasury and have 4,066,351,695 ordinary shares in issue (excluding Treasury shares).   The total number of voting rights in the Company is   4,066,351,695. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.   The Company confirms that, in accordance with DTR 5.5.1R, following the above purchase the percentage of voting rights attributable to the ordinary shares held in treasury is 6.12 per cent.   The table below contains detailed information of the individual trades made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) as part of the buyback programme.   Schedule of Purchases Shares purchased:   GSK plc (ISIN: GB00BN7SWP63) Date of purchases:   06 October 2025 Investment firm:      BNP Paribas SA     Aggregated information per trading venue: Venue   Number of ordinary shares purchased   Highest price paid (per ordinary share)(GBp)   Lowest price paid (per ordinary share)(GBp)   Volume weighted average price paid (per ordinary share) (GBp)   BATE   39,764   1,624.00p   1,595.00p   1,614.13p   CHIX   120,711   1,624.50p   1,594.00p   1,614.41p   XLON   179,525   1,624.50p   1,594.00p   1,613.80p       Individual transactions:   Number of Shares   Price per Share (GBp)   Trading venue   Date of transaction   Time of transaction   Transaction reference number   338   1600.0   XLON   06-Oct-2025   08:00:26   20251006146509644   185   1600.5   BATE   06-Oct-2025   08:01:01   20251006146510820   106   1600.5   CHIX   06-Oct-2025   08:01:01   20251006146510822   185   1600.5   XLON   06-Oct-2025   08:01:01   20251006146510824   370 &#x